Inherited retinal degenerations, including choroideremia, have traditionally lacked safe and effective therapies because it was considered impossible to modify the consequences of genetic mutations that cause irreversible, progressive, photoreceptor death and blindness. However, clinical trials demonstrated the safety and efficacy of gene augmentation therapy for patients with inherited retinal degenerations due to mutations in the RPE65 gene,1 resulting in approval by the US Food and Drug Administration of the first gene therapy for an inherited disease in December 2017. That landmark development has renewed interest in development of gene augmentation therapies; currently, 23 different clinical trials are underway, studying gene augmentation for at least 13 different genes that cause inherited retinal degenerations.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Duncan JL. Gene Therapy for Choroideremia—Progress and Remaining Questions. JAMA Ophthalmol. 2019;137(11):1254–1255. doi:10.1001/jamaophthalmol.2019.3295
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: